

**The YODA Project
Research Proposal Due Diligence Assessment**

Part 1: General Information	
YODA Project (Protocol) ID:	2018-3743
Date:	21 November 2018
Product Name:	Infliximab/ Ustekinumab
Therapeutic Area:	Immunology
Product Class:	Antirheumatic Agents - Biologic Response Modifiers
Condition(s) Studied:	Crohn's Disease
Protocol Number(s) and Title(s):	Infliximab: NCT00207766 C0168T26 NCT00207662 C0168T21 Ustekinumab: NCT00771667 C0743T26 NCT01369329 CNT01275CRD3001 NCT01369342 CNT01275CRD3002 NCT01369355 CNT01275CRD3003
Part 2: Data Availability	
Data Holder has authority to provide clinical trial data or development partner has agreed to share clinical trial data.	Yes
Comments:	
Data Holder has sharable electronic clinical trial data or data can be converted to electronic format.	Yes
Comments:	
De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.	Yes
Comments:	
The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.	Yes
Comments:	
Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).	Yes
Comments:	
Part 3: Data Availability Summary	
Based on the responses to the above Data Availability questions, the requested clinical trial data are available for a data sharing request.	Yes
Part 4: Proposal Review	
Question:	Response:
Summary-level CSR data is appropriate for the proposed analysis.	Yes
Participant-level data is appropriate for the proposed analysis.	No
A similar analysis is underway or completed/pending disclosure by Janssen.	No
Comments:	